A Phase 1/2 interventional study of Daily aspirin (ASA) and Split dose aspirin (ASA) in Preterm Birth and Preeclampsia, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to female participants aged 16 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Thomas Jefferson University · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 742 studies in Premature Birth with a site in United States — 103 open to participants now, 136 under way, 9 of them phase 3. Premature Birth · United States.
Among the 742 studies in Premature Birth with a site in United States, this one is the 84th largest by planned enrollment of the 529 interventional ones that give a count, is one of 23 that started in 2025, is one of 15 in phase 1/2, reaches primary completion later than 118 of the 135 other live ones, and was the 700th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →103 of the 742 studies in Premature Birth with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
University of South Carolina · Sites in United States
Ages 18+ · Women only
Columbia University · Sites in United States
Ages 18–40 · Women only
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18+ · Women only · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 1 days–3 days
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 16 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
742 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 68 · Phase 3 66 · Phase 4 23
First in 1987; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 85 across the 529 interventional studies, 104 across the 209 observational. Of the 542 that completed or were terminated, 145 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 742 have an industry lead sponsor. The 10 most frequent:
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
Thomas Jefferson University has 8 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
46 of the studies in Premature Birth with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04614714Phase 3University of California, DavisMilk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants | 2027-08-30 |
| NCT03797183University of Colorado, DenverGenesis Electrical Impedance Tomography (EIT): A Preliminary Study | 2026-11 |
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT01483079Baylor College of MedicinePost-Discharge Growth of Infants Who Received Donor Human Milk Products in the Neonatal Intensive Care Unit (NICU) | 2026-12 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
Add all 46 to your calendar (.ics) → With an account.
Among the 742 studies in Premature Birth with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aspirin is recommended in high risk patients to reduce the risk of preeclampsia and preterm birth, which are leading causes of both maternal and neonatal morbidity and mortality, but up to 20% will have these adverse outcomes despite therapy. Gaps in knowledge regarding pregnancy specific aspirin pharmacology and the relationship of aspirin response and pregnancy outcome, along with a lack of consensus on aspirin dosing has limited the effective use of this intervention. The investigators aim to apply principles of clinical pharmacology to determine how to optimally utilize this low cost medication to improve maternal/child health outcomes. This is a Phase I/II randomized controlled trial of high risk pregnancies recommended aspirin; participants will be randomized to take aspirin either 162mg once daily, or 81mg twice a day. Outcomes evaluated will include the difference in aspirin response between these two dosing regimens, the individual factors that impact aspirin pharmacology in pregnancy, and evaluate markers or aspirin response that may be associated with pregnancy outcome.
This is an unblinded randomized controlled Phase I/II trial comparing high risk singleton pregnancies randomized to 162mg daily (daily dose) vs 81mg q12hours (split dose). Participants will be enrolled prior to 16 weeks gestation. The primary outcome is platelet inhibition as assessed by PFA-100 epinephrine closure time, assessed 2-4 weeks after initiation and again at 28-32 weeks gestation. A subset of participants will be enrolled in a pharmacokinetic study to evaluate pharmacokinetics of aspirin in pregnancy at the two dosing intervals. Secondary outcomes include urine thromboxane at each visit, platelet associated microRNAs. Individual factors associated with aspirin pharmacokinetics and pharmacodynamics in pregnancy will be assessed. Finally, the relationship between these pharmacodynamic markers and pregnancy outcome will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
162mg aspirin daily
Drug: Daily aspirin (ASA)
81mg aspirin q12 hours
Drug: Split dose aspirin (ASA)
162mg aspirin taken daily
81mg aspirin q12hours
Aspirin Response PFA-100 epinephrine closure time (seconds)
Difference in PFA-100 epinephrine closure time (seconds)
Time frame: 2-4 weeks after aspirin initiation
Aspirin response (PFA-100 epinephrine closure time)
Difference in PFA-100 epinephrine closure time (seconds)
Time frame: 28-32 weeks gestation
Urinary thromboxane concentration
Difference in Urine thromboxane (AspirinWorks)
Time frame: 2-4 weeks after aspirin initiation
Urinary Thromboxane concentration
Difference in Urinary thromboxane (AspirinWorks)
Time frame: 28-32 weeks gestation
Inadequate aspirin response
Number of participants with PFA-100 epinephrine closure time\<150 seconds
Time frame: 2-4 weeks after aspirin initiation
Inadequate aspirin response
Number of participants with PFA-100 epinephrine closure time\<150seconds
Time frame: 28-32 weeks gestation
Preterm birth
Number of participants with Preterm birth\<37 weeks
Time frame: Delivery
Indicated preterm birth
Number of participants with Preterm birth\<37 weeks due to preeclampsia or fetal growth restriction
Time frame: delivery
Spontaneous preterm birth
Number of participants with spontaneous preterm birth \<37 weeks
Time frame: delivery
MicroRNAs
Fold-change from baseline for concentration of circulating microRNAs
Time frame: 2-4 weeks after aspirin initiation
MicroRNAs
Fold-change from baseline for concentration of circulating microRNAs
Time frame: 28-32 weeks gestation
Placental histopathology
Placental pathology per Amsterdam criteria. Number of participants with maternal vascular malperfusion, intervillous thrombosis
Time frame: Delivery
Birthweight
Infant birthweight (grams)
Time frame: Delivery
Fetal growth restriction
Number of participants diagnosed with Fetal growth restriction
Time frame: delivery
Hypertensive disorder of pregnancy
Number of participants diagnosed with Preeclampsia or gestational hypertension
Time frame: delivery
Gestational age at delivery
Gestational age at delivery (weeks)
Time frame: Delivery
Pregnancy loss<20 weeks
Number of participants with Pregnancy loss (delivery, demise, miscarriage)\<20 weeks gestation
Time frame: delivery
Fetal demise
Number of participants with Fetal demise diagnosed \>=20 weeks gestation
Time frame: delivery
Antepartum bleeding
Number of participants with any admission for antepartum bleeding
Time frame: Delivery
Abruption
Number of participants with Abruption diagnosed prior to or at delivery
Time frame: delivery
Placental hematoma
Number of participants with Placental hematoma suspected on ultrasound
Time frame: delivery
Postpartum hemorrhage
Number of participants with Postpartum hemorrhage \>1000ml
Time frame: Delivery
Adherence
Number of participants with Adherence\>75%
Time frame: 2-4 weeks after aspirin
Adherence
Number of participants with Adherence\>75%
Time frame: 28-32 weeks
Neonatal intraventricular hemorrhage Grade II or higher
Number of participants with infants found to have Neonatal IVH grade II or higher diagnosed on ultrasound post natally
Time frame: Neonatal discharge
Cordblood serum thromboxane
cordblood serum thromboxane concentration
Time frame: Delivery
Plan to share: Yes — Data will be submitted to NICHD DASH and can be requested through NICHD DASH
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: 1 year after study completion
Access criteria: Data will be submitted to NICHD DASH and may be requested through DASH
Data sharing details ↗ · dash.nichd.nih.gov
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jul 2029, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin